Mit kell tudnunk a cardialis amyloidosisról? A tünettantól a kezelésig [What should we know about cardiac amyloidosis? From clinical signs to treatment]

Systemic amyloidosis is a rare disease, in which the heart involvement is rather frequent and determines survival remarkably. Regarding the disease and organ involvement, new diagnostic procedures help to establish the diagnosis and to start the adequate treatment as soon as possible. Cardiac involv...

Full description

Saved in:
Bibliographic Details
Main Authors: Földeák Dóra Melinda
Nemes Attila
Kalapos Anita
Domsik Péter
Kormányos Árpád
Krenács László
Bagdi Enikő
Borbényi Zita
Format: Article
Published: 2017
Series:ORVOSI HETILAP 158 No. 46
doi:10.1556/650.2017.30872

mtmt:3336129
Online Access:http://publicatio.bibl.u-szeged.hu/16334
Description
Summary:Systemic amyloidosis is a rare disease, in which the heart involvement is rather frequent and determines survival remarkably. Regarding the disease and organ involvement, new diagnostic procedures help to establish the diagnosis and to start the adequate treatment as soon as possible. Cardiac involvement is more likely to be characterised by monoclonal immunglobulin free light chain (AL amyloidosis) type and transthyretin type. In case of AL amyloidosis, heart involvement can lead to serious consequences. Biomarker assessments for cardiac function are important to determine disease severity at the beginning and to measure response to the treatment. In case of amyloidosis, the incidence of the heart involvement grows with age. The prevalence is not known exactly, but probably there are more cases than recognised. The authors present the clinical signs and diagnostic methods, emphasizing the importance of the cardiac examination methods. Orv Hetil. 2017; 158(46): 1811-1818.
Physical Description:1811-1818
ISSN:0030-6002